| 產(chǎn)品名稱(chēng) |
IFGCP-F1BA10 |
| 商品貨號(hào) |
B164830 |
| Organism |
Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
| Cell Type |
hybridoma: B lymphocyte |
| Product Format |
frozen |
| Morphology |
lymphoblast |
| Culture Properties |
suspension |
| Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disclosure |
This material is cited in a US or other Patent and may not be used to
infringe the claims. Depending on the wishes of the Depositor, ATCC may be
required to inform the Patent Depositor of the party to which the material was
furnished. This material may not have been produced or characterized by ATCC. |
| Derivation |
Spleen cells were fused with Sp2/0 myeloma cells. |
| Genes Expressed |
immunoglobulin; monoclonal antibody; against human gamma interferon (IFN) |
| Cellular Products |
immunoglobulin; monoclonal antibody; against human gamma interferon (IFN) |
| Tumorigenic |
Yes |
| Effects |
Yes, forms ascites in pristane primed BALB/c mice |
| Comments |
Animals were immunized with a synthetic polypeptide 19 residues long (NH2-Lys-Thr-Gly-Lys-Arg-Lys-Arg-Ser-Gln-Met-Leu-Phe-Arg-Gly-Arg-Arg-Ala-Ser-Gln-COOH) bound to KLH. Spleen cells were fused with Sp2/0 myeloma cells. |
| Complete Growth Medium |
HB101 medium (Hana Biologicals), 99%; fetal bovine serum, 1% - OR - Dulbecco's modified Eagle's medium, 90%; fetal bovine serum, 10%
|
| Subculturing |
Medium Renewal: Every 2 to 3 days Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 4 X 10 exp4 cells/ml and maintain at or below 8 X 10 exp5 cells/ml. |
| Cryopreservation |
fetal bovine serum, 90%; DMSO, 10% |
| Isotype |
IgG1 |
| Name of Depositor |
Amgen, Inc. |
| Deposited As |
mouse (B cell); mouse (myeloma) |
| U.S. Patent Number |
|
| References |
Altrock BW. Monoclonal antibodies which specifically bind to human immune interferon. US Patent 4,599,306 dated Jul 8 1986
|
